DEF: GRI Bio Proposes Reverse Stock Split Amid Delisting Concerns

GRI Bio, Inc. is seeking stockholder approval for a reverse stock split to address Nasdaq listing deficiencies and avoid potential delisting.

Summary

• A special meeting of stockholders is scheduled for January 15, 2026, to vote on two proposals: a reverse stock split and an adjournment proposal.
• The primary proposal is to amend the company's Certificate of Incorporation to effect a reverse stock split of common stock by a ratio of not less than one-for-two and not more than one-for-30.
• The board of directors will have the sole discretion to set the exact ratio within this range and to decide whether or not to effect the split, even if approved by stockholders.
• The reverse stock split is primarily intended to increase the per-share market price of common stock to meet Nasdaq's minimum bid price requirement of $1.00.
• The company received a notice on November 26, 2025, from Nasdaq regarding non-compliance with the minimum stockholders' equity requirement of $2,500,000.
• As of December 18, 2025, the closing price of the common stock on Nasdaq Capital Market was $0.3697 per share.
• The company plans to submit a Compliance Plan to Nasdaq by January 10, 2026, to address the stockholders' equity deficiency, noting that stockholders' equity exceeded $2.5 million after its most recent public offering.
• The board also recommends approval of an adjournment of the Special Meeting, if necessary, to solicit further proxies for the reverse stock split proposal.
• The reverse stock split would reduce the number of outstanding shares from 10,121,060 (as of the record date) to between 5,060,530 and 337,369 shares, depending on the ratio.
• No fractional shares will be issued; stockholders will receive cash payments in lieu of fractional shares.

Sentiment

Score: 3

Explanation: The sentiment is negative due to the company facing delisting threats from Nasdaq for both minimum bid price and stockholders' equity. While management is taking steps (reverse split proposal, compliance plan), the necessity of these actions, coupled with a history of prior reverse splits and the inherent risks, indicates significant challenges and uncertainty regarding the company's future stability and stock performance.

Positives

• The company's stockholders' equity exceeded $2.5 million immediately following its most recently completed public offering, which is a positive step towards addressing the Nasdaq Stockholders' Equity Requirement.
• The board of directors is proactively seeking stockholder approval for a reverse stock split to address Nasdaq listing deficiencies and potentially avoid delisting, demonstrating an effort to maintain market access.

Negatives

• The company's common stock closing price was $0.3697 per share on December 18, 2025, significantly below Nasdaq's $1.00 minimum bid price requirement.
• GRI Bio received a delisting notice on November 26, 2025, for non-compliance with Nasdaq's minimum stockholders' equity requirement of $2,500,000.
• Given the company's history of prior reverse stock splits, it is likely ineligible for a standard 180-day compliance period for the minimum bid price requirement.
• There is no assurance that the Compliance Plan for stockholders' equity will be accepted by Nasdaq or that the company will regain and maintain compliance.
• The company will need to obtain substantial additional funding for its continuing operations, with no assurance that such financing will be available when needed.

Risks

• Negative perception of reverse stock splits by investors, analysts, and market participants.
• Stock prices of some companies, including GRI Bio previously, have declined, sometimes significantly, following reverse stock splits.
• Possible adverse effect on liquidity due to a reduced number of outstanding shares.
• Costs associated with implementing a reverse stock split.
• No assurance that the reverse stock split will achieve desired results, such as a sustained market price above $1.00 or meeting other Nasdaq listing requirements.
• The market price per share after the reverse stock split may not rise in proportion to the reduction in outstanding shares.
• The reverse stock split may not attract brokers and investors who avoid lower-priced stocks.
• The reverse stock split may not increase the company's ability to attract and retain employees and other service providers.
• The increase in authorized but unissued shares could be dilutive to existing stockholders if issued in the future.
• If delisted, trading would move to OTC Markets or pink sheets, making it more difficult for investors to dispose of shares or obtain accurate price quotations.
• Delisted common stock priced below $5.00 would likely be classified as a 'penny stock,' imposing additional sales practice requirements on broker-dealers and making trading more difficult and the market less efficient.

Future Outlook

The company intends to effect a reverse stock split to regain compliance with Nasdaq's minimum bid price requirement and improve its prospects of maintaining listing. It also plans to submit a compliance plan for the stockholders' equity deficiency. However, there is no assurance that the reverse stock split will result in a sustained bid price above $1.00 or that the company will meet other listing requirements. The company will need substantial additional funding and intends to raise capital through equity issuances (including an At-the-Market offering) or debt, but there is no guarantee such financing will be available.

Management Comments

• "We believe hosting a virtual meeting enables greater stockholder attendance and participation from any location around the world, improves meeting efficiency and our ability to communicate effectively with our stockholders, and reduces the cost and environmental impact of the Special Meeting." W. Marc Hertz, Ph.D., President and Chief Executive Officer.
• "Our board of directors has reserved the right, notwithstanding our stockholders approval of the proposed amendment to the Amended and Restated Certificate of Incorporation at the Special Meeting, to abandon the proposed amendment at any time (without further action by our stockholders) before the certificate of amendment is filed with the Secretary of State of the State of Delaware."
• "Our board of directors unanimously recommends a vote FOR approval of the Amendment Proposal."
• "Our board of directors unanimously recommends a vote FOR approval of the Adjournment Proposal."

Industry Context

The company's situation reflects a common challenge for smaller public companies, particularly in the biotechnology or early-stage development sectors, where maintaining Nasdaq listing requirements can be difficult due to fluctuating stock prices and capital needs. Low stock prices often deter institutional investors and can lead to a negative perception, impacting liquidity and the ability to raise further capital. Reverse stock splits are a frequent, though often temporary, measure used by companies to avoid delisting and improve marketability, but they carry inherent risks of not achieving sustained price improvement or positive investor sentiment.

Corporate Governance

Stakeholder Impact

• **Shareholders**: Potential for increased stock price to maintain Nasdaq listing, but also risks of further price decline, reduced liquidity, and dilution from future equity issuances. Those with fractional shares will receive cash payments.
• **Employees**: The ability to attract and retain employees and other service providers could be impacted if the stock price remains low or declines further.
• **Investors (Institutional)**: The reverse stock split aims to make the stock more attractive to institutional investors who often avoid lower-priced stocks, but there's no guarantee of success.
• **Creditors**: The company's need for substantial additional funding and potential reevaluation of operating plans if funding is not secured could impact its ability to meet obligations.

Next Steps

• Stockholders to vote on the reverse stock split and adjournment proposals at the Special Meeting on January 15, 2026.
• The company to submit a Compliance Plan to Nasdaq by January 10, 2026, to address the stockholders' equity deficiency.
• If approved by stockholders, the board of directors will decide whether and at what ratio (between 1-for-2 and 1-for-30) to effect the reverse stock split.
• If the reverse stock split is effected, a certificate of amendment will be filed with the Secretary of State of Delaware.
• Final voting results will be published in a Current Report on Form 8-K within four business days after the Special Meeting.

Key Dates

Recommendation

The company is facing significant challenges, including Nasdaq delisting threats due to a low stock price and non-compliance with stockholders' equity requirements. While the proposed reverse stock split is a necessary step to address these issues, its effectiveness is uncertain, and the company has a history of prior splits without sustained improvement. The need for substantial future funding adds to the risk. A 'hold' recommendation is appropriate for existing investors to monitor the outcome of the special meeting and the company's ability to regain and maintain Nasdaq compliance, as well as its capital raising efforts. New investors should exercise extreme caution due to the high risk profile and lack of clear positive catalysts beyond addressing immediate survival concerns.

Keywords

Reverse Stock Split, Nasdaq Listing, Delisting Risk, Stockholders' Equity, Minimum Bid Price, Proxy Statement, Corporate Governance, Capital Raise, GRI Bio